References
- American Cancer Society. What Are the Key Statistics for Chronic Lymphocytic Leukemia? Available at: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/key-statistics.html [Last accessed 19 December 2017]
- SEER Program. Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia (CLL). Available at: https://seer.cancer.gov/statfacts/html/clyl.html [Last accessed 19 December 2017]
- Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v78-84
- National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2018. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf [Last accessed 19 December 2017]
- Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
- Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007;64:234-46
- Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84
- Blankart CR, Koch T, Linder R, et al. Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis 2013;8:32
- Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, et al. Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leuk Res 2014;38:84-90
- Lafeuille MH, Vekeman F, Wang ST, et al. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1146-54
- Stephens JM, Gramegna P, Laskin B, et al. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther 2005;12:460-6
- Casado LF, García Marco JA, Gilsanz F, et al. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia]. Gac Sanit 2011;25:274-81
- Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:225-34
- Muller D, Fischer K, Kaiser P, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2016;57:1130-9
- Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535-44
- Truven Health Analytics. Truven Health MarketScan Research Databases. 2012. Available at: http://truvenhealth.com/portals/0/assets/HP_11517_0912_MarketScanResearchDatabasesForHP_SS_WEB.pdf [Last accessed 19 December 2017]
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
- Elixhauser A, Steiner C, Kruzikas D. HCUP Methods Series Report # 2004-1. Comorbidity Software Documentation 2004. Available at: https://www.hcup-us.ahrq.gov/reports/methods/ComorbiditySoftwareDocumentationFinal.pdf [Last accessed 19 December 2017]
- Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall/CRC, 1994
- Squires DA. Explaining high health care spending in the United States: an international comparison of supply, utilization, prices, and quality. Issue Brief (Commonw Fund) 2012;10:1-14
- Arnieri B, Bernaards C, Wilhelm K, et al. Changing demographics and treatment patterns in patients the United States with chronic lymphocytic leukemia in the first-line setting as assessed using a novel electronic health record database. Blood 2016;128:4787
- Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425-37